Bioasis Appoints Saltarelli as Non-Executive Director
31 May 2019 - - US-based pre-clinical, research-stage biopharmaceutical company Bioasis Technologies Inc (OTCQB: BIOAF) (TSX.V: BTI) has appointed Mario Saltarelli, M.D., Ph.D., as non-executive director of the Bioasis board of directors.

Saltarelli served on Bioasis' scientific advisory board since June 2018.

He has over 20 years of leadership experience in the biopharmaceutical industry. Currently, he is Chief Medical officer at Entrada Therapeutics, and held CMO positions at Syntimmune and Annexon Biosciences.

Saltarelli previously held executive leadership positions at Vertex, Mallinckrodt, Shire, AbbVie, and Pfizer.

Prior to entering the pharmaceutical industry, Saltarelli was an Assistant Professor of Neurology at Emory University School of Medicine in Atlanta.

Saltarelli holds an M.D. and a Ph.D. in neuroscience from Johns Hopkins University School of Medicine in Baltimore and also completed his neurology residency training at Johns Hopkins Hospital. Saltarelli earned his B.S. in psychology from the University of Illinois at Urbana-Champaign.

Bioasis Technologies is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need.

The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders.

Bioasis' internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher's Disease Type II.

The company maintains headquarters in Guilford, Connecticut.